• Please log in or register to access this feature.

Embryonic Stem Cells/induced Pluripotent Stem Cells

Brief Report: Human Pluripotent Stem Cell Models of Fanconi Anemia Deficiency Reveal an Important Role for Fanconi Anemia Proteins in Cellular Reprogramming and Survival of Hematopoietic Progenitors†‡§

  1. Sun K. Yung1,2,
  2. Katarzyna Tilgner1,2,
  3. Maria H. Ledran1,
  4. Saba Habibollah1,2,
  5. Irina Neganova1,2,
  6. Chatchawan Singhapol3,
  7. Gabriele Saretzki3,
  8. Miodrag Stojkovic4,
  9. Lyle Armstrong1,2,
  10. Stefan Przyborski5,¶,*,
  11. Majlinda Lako1,2,‖,*

Article first published online: 24 APR 2013

DOI: 10.1002/stem.1308

Issue

STEM CELLS

STEM CELLS

Volume 31, Issue 5, pages 1022–1029, May 2013

Additional Information

How to Cite

Yung, S. K., Tilgner, K., Ledran, M. H., Habibollah, S., Neganova, I., Singhapol, C., Saretzki, G., Stojkovic, M., Armstrong, L., Przyborski, S. and Lako, M. (2013), Brief Report: Human Pluripotent Stem Cell Models of Fanconi Anemia Deficiency Reveal an Important Role for Fanconi Anemia Proteins in Cellular Reprogramming and Survival of Hematopoietic Progenitors. STEM CELLS, 31: 1022–1029. doi: 10.1002/stem.1308

Author Information

  1. 1

    Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom

  2. 2

    NESCI, Newcastle University, Newcastle, United Kingdom

  3. 3

    Institute for Ageing and Health, Newcastle University, Newcastle, United Kingdom

  4. 4

    Department of Human Genetics, University of Kragujevac, Serbia

  5. 5

    School of Biological and Biomedical Sciences, Durham University, Durham, United Kingdom

  1. Telephone: +44-191-334-3988

  2. ‖

    Telephone: +44-191-241-8688; Fax: +-191-241-8666

*School of Biological and Biomedical Sciences, Durham University, Durham, U.K.

  1. †

    Author contributions: S.Y., K.T., and M.L.: performed experiments, data analysis, and final approval of manuscript; S.H., I.N., C.S., and G.S.: performed some of the experiments and final approval of manuscript; M.S.: conception and design, fund raising, and final approval of manuscript; L.A.: conception and design, manuscript writing, fund raising, and final approval of manuscript; S.P.: performed some of the experiments, collection and analysis of the data, contributed to manuscript writing, and final approval of manuscript; M.L.: conception and design, performed experiments, data analysis, manuscript writing, fund raising, and final approval of manuscript. S.K.Y. and K.T. contributed equally to this article.

  2. ‡

    Disclosure of potential conflicts of interest is found at the end of this article.

  3. §

    First published online in STEM CELLSEXPRESS December 27, 2012.

  4. Telephone: +44-191-334-3988

  5. ‖

    Telephone: +44-191-241-8688; Fax: +-191-241-8666

Publication History

  1. Issue published online: 24 APR 2013
  2. Article first published online: 24 APR 2013
  3. Accepted manuscript online: 27 DEC 2012 01:44AM EST
  4. Manuscript Accepted: 1 DEC 2012
  5. Manuscript Received: 2 AUG 2012

Funded by

  • Leukemia and Lymphoma Research. Grant Number: 10050
  • Fanconi Anemia Research Fund U.S.
  • Fanconi Hope U.K.
  • Regenerative Medicine through the collaboration agreement from the Conselleria de Sanidad (Generalitat Valenciana)
  • Instituto de Salud Carlos III (Ministry of Science and Innovation), Spain

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (5032K)

Keywords:

  • Fanconi anemia;
  • Human-induced pluripotent stem cells;
  • Human embryonic stem cells;
  • Embryonic hematopoiesis

Abstract

Fanconi anemia (FA) is a genomic instability disorder caused by mutations in genes involved in replication-dependant-repair and removal of DNA cross-links. Mouse models with targeted deletions of FA genes have been developed; however, none of these exhibit the human bone marrow aplasia. Human embryonic stem cell (hESC) differentiation recapitulates many steps of embryonic hematopoietic development and is a useful model system to investigate the early events of hematopoietic progenitor specification. It is now possible to derive patient-specific human-induced pluripotent stem cells (hiPSC); however, this approach has been rather difficult to achieve in FA cells due to a requirement for activation of FA pathway during reprogramming process which can be bypassed either by genetic complementation or reprogramming under hypoxic conditions. In this study, we report that FA-C patient-specific hiPSC lines can be derived under normoxic conditions, albeit at much reduced efficiency. These disease-specific hiPSC lines and hESC with stable knockdown of FANCC display all the in vitro hallmarks of pluripotency. Nevertheless, the disease-specific hiPSCs show a much higher frequency of chromosomal abnormalities compared to parent fibroblasts and are unable to generate teratoma composed of all three germ layers in vivo, likely due to increased genomic instability. Both FANCC-deficient hESC and hiPSC lines are capable of undergoing hematopoietic differentiation, but the hematopoietic progenitors display an increased apoptosis in culture and reduced clonogenic potential. Together these data highlight the critical requirement for FA proteins in survival of hematopoietic progenitors, cellular reprogramming, and maintenance of genomic stability. STEM CELLS 2013;31:1022–1029

View Full Article with Supporting Information (HTML) Get PDF (5032K)